Xeris Biopharma Holdings (XERS) Revenue (2020 - 2026)

Xeris Biopharma Holdings' Revenue history runs 7 years deep, the most recent figure standing at $83.1 million for Q1 2026.

• Quarterly Revenue rose 38.27% year-over-year to $83.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $314.9 million (up 41.47% YoY) and the FY2025 annual result came in at $291.8 million, up 43.72% from the prior year.
• Revenue was $83.1 million for Q1 2026 at Xeris Biopharma Holdings, down from $85.8 million in the prior quarter.
• Across five years, Revenue topped out at $85.8 million in Q4 2025 and bottomed at $22.1 million in Q1 2022.
• A 5-year average of $50.1 million and a median of $48.1 million in 2024 frame the typical range for Revenue.
• Annual changes were most pronounced in 2022 — Revenue jumped 184.15% — and 2024, when it gained 12.31%.
• Xeris Biopharma Holdings' Revenue stood at $33.1 million in 2022, then surged by 33.93% to $44.4 million in 2023, then soared by 35.39% to $60.1 million in 2024, then jumped by 42.78% to $85.8 million in 2025, then slipped by 3.12% to $83.1 million in 2026.
• Business Quant data shows XERS's Revenue at $83.1 million in Q1 2026, $85.8 million in Q4 2025, and $74.4 million in Q3 2025.